| Autor: |
Frade VP; Universidade Federal de São João del-Rei, Divinópolis, Minas Gerais, Brazil., Moreira CHV; Universidade de São Paulo, Instituto de Medicina Tropical de São Paulo, São Paulo, São Paulo, Brazil., Sabino EC; Instituto de Infectologia Emilio Ribas, São Paulo, São Paulo, Brasil., Bedor DCG; Universidade Federal de Pernambuco, Recife, Pernambuco, Brazil., Ghilard FR; Universidade de São Paulo, Instituto de Medicina Tropical de São Paulo, São Paulo, São Paulo, Brazil., Oliveira CDL; Universidade Federal de São João del-Rei, Divinópolis, Minas Gerais, Brazil., Sanches C; Universidade Federal de São João del-Rei, Divinópolis, Minas Gerais, Brazil. |
| Abstrakt: |
The present study aimed to establish a population pharmacokinetic (PopPK) modeling of benznidazole (BZD) in Brazilian patients with chronic Chagas disease. This was part of a Brazilian prospective cohort study with eight patients diagnosed with Chagas disease during the beginning of BZD treatment up to the 60th day. On the 15th day of treatment, a blood sampling was collected and analyzed. A one-compartment PK model was developed using Pmetrics. Patients with an average age of 50.3 (SD: 6.2) years old, 6 female patients and 2 males, 70.2 kg (14.2), receiving a 5 mg/Kg/day dose were included. PK parameters estimated for CL, V and Ka were 6.27 L/h, 38.97 L and 1.66 h-1, respectively. This is the first study to establish a population pharmacokinetic modeling of BZD in Brazilian patients with chronic Chagas disease. Therefore, further studies are needed to obtain the complete characterization of BZD pharmacokinetics. |
